Stockscreener 앱 받기
5.99
5.07%
-0.32
전일 마감가:
$6.31
열려 있는:
$6.09
하루 거래량:
17,607
Relative Volume:
0.01
시가총액:
$13.84M
수익:
-
순이익/손실:
$-67.28M
주가수익비율:
-0.0633
EPS:
-94.66
순현금흐름:
$-9.80M
1주 성능:
-28.78%
1개월 성능:
-24.70%
6개월 성능:
+99.67%
1년 성능:
+17.81%
1일 변동 폭
$5.95
$6.5895
1주일 범위
$5.95
$9.24
52주 변동 폭
$2.098
$23.01
Portage Biotech Inc Stock (PRTG) Company Profile
PRTG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRTG
Portage Biotech Inc
|
5.99 | 13.84M | 0 | -67.28M | -9.80M | -94.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Portage Biotech Inc Stock (PRTG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-07 | 개시 | H.C. Wainwright | Buy |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-02 | 개시 | B. Riley Securities | Buy |
| 2021-08-19 | 개시 | Cantor Fitzgerald | Overweight |
Portage Biotech Inc 주식(PRTG)의 최신 뉴스
Contrasting Portage Biotech (NASDAQ:PRTG) & Hypera (OTCMKTS:HYPMY) - Defense World
Citadel Advisors LLC Buys Shares of 15,431 Portage Biotech Inc. (NASDAQ:PRTG) - Defense World
symbol__ Stock Quote Price and Forecast - CNN
Portage Biotech (PRTG) Forms Strategic Subscription Agreement | - GuruFocus
Portage Biotech and Compedica Stock-for-Stock Exchange | PRTG St - GuruFocus
Portage Biotech and Compedica Forge Strategic Alliance with Stock Exchange - TipRanks
Portage Biotech acquires stake in Compedica for $5 million - Investing.com
Portage Biotech acquires stake in Compedica for $5 million By Investing.com - Investing.com Canada
Portage Biotech and Compedica Stock-for-Stock Exchange - The Manila Times
Portage Biotech Stakes Claim in $4B Diabetic Ulcer Market: Strategic Deal Targets 18.6M Patient Opportunity - Stock Titan
Short Interest in Portage Biotech Inc. (NASDAQ:PRTG) Declines By 56.6% - Defense World
Portage Biotech Appoints New Auditor Following Marcum Resignation - TipRanks
Portage Biotech (NASDAQ:PRTG) Stock Price Down 4.4% – Here’s What Happened - Defense World
Portage Biotech Stock Surges On New Preclinical Data In Mesothelioma Trial: Retail Gets More Bullish - Asianet Newsable
Investing in Portage Biotech Inc (PRTG) Is Getting More Attractive - knoxdaily.com
Market Analysts see Portage Biotech Inc [PRTG] gaining to $26. Time to buy? - dbtnews.com
Earnings Week Awaits As US Futures Hold Steady - Finimize
Portage Biotech (PRTG) Reports Promising Preclinical Results for PORT-7 | PRTG Stock News - GuruFocus
Insider Activity Signals Optimism for Portage Biotech (PRTG) - GuruFocus
Portage Biotech Stock Surges On New Preclinical Data In Mesothelioma Trial: Retail Gets More Bullish By Stocktwits - Investing.com India
Portage Biotech Reports Confirmatory Preclinical Results in Meso - GuruFocus
The Future of Portage Biotech Inc: Analyzing PRTG - investchronicle.com
How analysts predict Portage Biotech Inc (PRTG) will perform this quarter? - uspostnews.com
Portage Biotech Stock Surges As It Prepares For Human Trial - Benzinga
Portage Biotech stock soars on promising preclinical results By Investing.com - Investing.com Nigeria
Portage Biotech stock soars on promising preclinical results - Investing.com Australia
Portage Biotech’s PORT-7 shows efficacy in mesothelioma preclinical study - TipRanks
Top Premarket Gainers - marketscreener.com
Portage Biotech Announces Preclinical Success for PORT-7 in Mesothelioma - TipRanks
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - The Manila Times
New Cancer Breakthrough: PORT-7 Outperforms Standard Treatment in Mesothelioma Study - Stock Titan
Insider Stock Buying Reaches US$2.15m On Portage Biotech - Yahoo
Portage Biotech Inc (PRTG) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
PRTG Stock on the Rise: A Promising Investment - investchronicle.com
Short Interest in Portage Biotech Inc. (NASDAQ:PRTG) Rises By 2,134.8% - Defense World
SoftBank Group (OTCMKTS:SFTBF) Stock Crosses Below 200-Day Moving Average – What’s Next? - Defense World
iAnthus Capital Holdings, Inc. (OTCMKTS:ITHUF) Short Interest Up 2,600.0% in March - Defense World
Corning Natural Gas (OTCMKTS:CNIG) Shares Pass Below 200-Day Moving Average – Here’s What Happened - Defense World
Scorpio Gold (OTCMKTS:SRCRF) Share Price Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Portage Biotech (PRTG) Resumes Key Clinical Trial Phase - GuruFocus
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Nasdaq Gains Over 50 Points; JPMorgan Posts Upbeat Earnings - Benzinga
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX - Yahoo Finance
CVS Health Corporation (CVS): A Bull Case Theory - Yahoo Finance
Biotech CEOs, VCs urge Cassidy, Senate to ease impact of FDA cuts - Yahoo Finance
ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple - Yahoo Finance
Cannara Biotech Inc.'s (CVE:LOVE) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance
Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors - Yahoo Finance
General Oncology Appoints Seasoned Biotech Executive Abid Ansari as Chief Financial Officer - Yahoo Finance
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - Yahoo Finance
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Portage Biotech Inc (PRTG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):